G protein-coupled receptor up-regulated in prostate cancer and uses thereof
CA 2385032 C · Owner: Raitano, Arthur B. · Inventors: Jakobovits, Aya; Mitchell, Steve C.; Afar, Daniel E. H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein, are described. PHOR-1 is a G protein-coupled receptor with homology to receptors involved in olfaction. PHOR-1 in normal human tissues is restricted to prostate, and this gene is highly over-expressed in prostate cancer as well as in cancers of the kidney uterus, cervix, stomach and rectum. Consequently PHOR-1 provides a diagnostic and/or , therapeutic target for prostate cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 5, 2000 and granted December 10, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 5, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 5, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.